| European Case Law Identifier: | ECLI:EP:BA:2011:T168510.20110606 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 06 June 2011 | ||||||||
| Case number: | T 1685/10 | ||||||||
| Application number: | 04021889.3 | ||||||||
| IPC class: | A61K 31/44 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | The use of inhibitors of the renin-angiotensin system | ||||||||
| Applicant name: | Ark Therapeutics Limited, et al | ||||||||
| Opponent name: | LES LABORATOIRES SERVIER TEVA PHARMACEUTICAL INDUSTRIES, LTD. Merck & Co., Inc. Sanofi-Aventis Deutschland GmbH |
||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | All requests: sufficiency of disclosure (no): insufficient tests | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t101685eu1.html
Date retrieved: 17 May 2021